Fiscal 2021 Second Quarter Highlights Net sales of $72.8 million increased 4.0% compared to the prior-year quarter Gross margin declined 410 basis points year over year to 55.2% GAAP loss per share of $0.11 and adjusted earnings per share of $0.01 Cash and cash equivalents on November 30, 2020 were

LATHAM, N.Y. --(BUSINESS WIRE)--Jan. 4, 2021-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 29, 2020-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 9, 2020-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the second quarter of

Represents Largest Catheter Based Thromboaspiration Study Completed to Date LATHAM, N.Y. --(BUSINESS WIRE)--Nov. 12, 2020-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology,

Fiscal 2021 First Quarter Highlights Net sales of $70.2 million increased 6.3% compared to the prior-year quarter, inclusive of the previously disclosed $5.2 million order from the National Health Service ( NHS ) in the UK Gross margin declined 700 basis points year over year to 50.9% GAAP loss per

ADVANCED MEDICAL TECHNOLOGY SAFELY 1 & EFFECTIVELY TREATS PAD, CLI, ISR LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 21, 2020-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today

LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 17, 2020-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of

LATHAM, N.Y. --(BUSINESS WIRE)--Aug. 17, 2020-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced the enrollment of the first patient in the PATHFINDER I:

LATHAM, N.Y. --(BUSINESS WIRE)--Aug. 3, 2020-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, will

Fiscal 2020 Fourth Quarter Highlights Net sales of $58.3 million decreased 18.1% compared to the prior-year quarter Gross margin declined 630 basis points year over year to 51.8% GAAP loss per share of $4.10 , inclusive of approximately $4.14 of goodwill impairment; adjusted loss per share of $0.06

LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 23, 2020-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the fourth quarter and

LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 8, 2020-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and

LATHAM, N.Y. --(BUSINESS WIRE)--May 7, 2020-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and

Fiscal 2020 Third Quarter Highlights Net sales of $69.8 million increased 6.5% compared to the prior-year quarter Gross margin declined 40 basis points to 57.8% year over year GAAP loss per share of $0.15 ; adjusted earnings per share of $0.01 Launched PATHFINDER I Registry to evaluate performance

LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of fiscal year 2020

LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will present at the following two investor conferences in March:

LATHAM, N.Y. --(BUSINESS WIRE)--Feb. 6, 2020-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has appointed Stephen Trowbridge to the role of Executive

LATHAM, N.Y. --(BUSINESS WIRE)--Jan. 16, 2020-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced the launch of the PATHFINDER I: Post-Market Registry (PATHFINDER

Fiscal 2020 Second Quarter Highlights Net sales of $70.0 million , flat compared to the prior-year quarter Gross margin increased 140 basis points year over year to 59.3% GAAP loss per share of $0.07 ; adjusted earnings per share of $0.06 Announces the acquisition of C3 Wave PICC tip location